MAPK (mitogen-activated protein kinase) pathways are among the most frequently deregulated signalling events in cancer. Among the critical targets of MAPK activities are members of the AP-1 (activator protein 1) transcription factor, a dimeric complex consisting of Jun, Fos, Maf and ATF (activating transcription factor) family DNA-binding proteins. Depending on the cellular context, the composition of the dimeric complexes determines the regulation of growth, survival or apoptosis. JNK (c-Jun N-terminal kinase), p38 and a number of Jun and Fos family proteins have been analysed for their involvement in oncogenic transformation and tumour formation. These data are also emerging for the ATF components of the AP-1 factor. The aim of the present review is to provide an overview of the functions of two ATF family proteins, ATF2 and ATF7, in mammalian development and their potential functions in tumour formation.
be activated by growth factors via the Ras/ERK (extracellularsignal-regulated kinase) pathway (Thr 71 phosphorylation) or via RalGDS (guanine nucleotide dissociation stimulator)/Src/p38 pathways (Thr 69 phosphorylation) [9] [10] [11] . Apart from the regulation by MAPKs, a variety of reports have described a number of regulatory phosphorylation events mediated by additional signalling pathways. For example, ATF2 was found to be activated by human VRK1 (vaccinia-related kinase 1) on two sites, Ser 62 and Thr 73 , in its activation domain [12] . In addition, PKC (protein kinase C) can phosphorylate ATF2 on Ser 121 , which may be important for late phases of the ATF2-mediated stress response [13] .
ATF2 has also been shown to be phosphorylated in its extreme C-terminus, on Ser 490 and Ser 498 , by ATM (ataxia telangiectasia mutated) protein kinase [14] . This phosphorylation was shown to be important for the intra-S-phase checkpoint activation, following ionizing radiation. ATM-mediated phosphorylation of ATF2 determines its localization into DNA repair foci, where it co-localizes with components of the DNA repair machinery, including Rad50, Nbs1 and Mre11. The recruitment of ATF2 to irradiationinduced foci, independent of its transcription-activating functions, points to a possible role as a sensor/adaptor at early stages of the DNA damage response [14] . Genetically modified mice in which the ATM phosphoacceptor sites were mutated showed increased sensitivity to ionizing radiation compared with wild-type ATF2 mice [15] . In addition, these ATF2 mutant mice showed increased incidence of spontaneous and chemically induced tumour induction, suggesting the importance of ATF2 phosphorylation by ATM in the acute cellular response to DNA damage and maintenance of genomic stability. ATF7 can be activated by phosphorylation on Thr 51 and Thr 53 (which correspond to Thr 69 and Thr 71 in ATF2) by p38, but not by JNK [16] . ATF7 also contains a lysine residue (Lys 118 ), which is specifically targeted by the SUMO (small ubiquitin-related modifier) machinery [16, 17] . SUMO conjugation with ATF7 delays its nuclear transport and impairs ATF7 transactivation activity by inhibition of its binding to specific sequences in target gene promoters [17] .
ATF2 in transcription-regulating complexes
In unstimulated conditions, ATF2 is maintained in a transcriptionally inactive form by intramolecular binding of its C-terminal DNA-binding domain to its N-terminal activation domain [18] . Binding of transcriptional co-activator and histone acetyltransferase CBP [CREB (CRE-elementbinding protein)-binding protein] or the adenovirus 13S E1A protein to the bZIP region alleviates the intramolecular inhibition and leads to activation of transcription [19] . ATF2 also interacts with the transcriptional co-activator p300. This complex formation is important for the regulation of c-Jun gene expression in response to inducers of cell differentiation such as retinoid acid or adenovirus E1A in mouse embryonal carcinoma cells [20] . In contrast, interaction with the ATPdependent helicase TIP49b results in the down-regulation of ATF2-dependent transcription activity [21] . ATF2 activity can be regulated by additional mechanisms, including nuclear localization [22] or the control of its stability and degradation [23] [24] [25] . The control of ATF2 degradation was demonstrated to be dependent on phosphorylation [23] [24] [25] [26] . Additionally, ATF2 activity can be regulated indirectly by the SUMOylation of heterodimerization partners, e.g. ATF7 [17, 27] . This process delays nuclear transport and inhibits binding of the dimeric complex to specific target genes.
Developmental functions of ATF2 and ATF7 revealed by mouse knockout studies
The first Atf2 mouse knockout published revealed decreased postnatal viability and growth of animals, as well as defects in endochondral ossification and in the central nervous system [28] . However, this knockout was subsequently shown to be hypomorphic, because it retained some of the ATF2 activity due to alternative splicing in the targeted allele [29] . Another knockout of ATF2 (Atf2 0/0 ) was generated by the deletion of the DNA-binding domain, which produced, at least transcriptionally, a functional null mutation. All of the Atf2 0/0 mutant mice died shortly after birth because of severe respiratory distress [29] . Furthermore, a knockin mutant mouse line in which the Thr 69 and Thr 71 (Thr  51 and Thr   53 in mouse ATF2) phosphorylation sites within the transcription activation domain are mutated into alanine (Atf2 AA ) leads to a similar phenotype and to invariable death at birth, confirming the importance of these phosphorylation sites for ATF2 activity [30] .
A study published in 2011 by Ackermann et al. [31] demonstrated that the perinatal death resulting from loss of ATF2 functions in mouse embryos is likely to be caused by defects in the development of the brainstem. Here, ATF2 is involved in functions that safeguard specific sets of facial motor neurons from undergoing neurodegeneration and apoptosis. Specifically, ATF2-deficient neurons express increased levels of phosphorylated (activated) JNK and p38 concomitant with higher rates in the phosphorylation of specific markers of neurodegeneration, e.g. neurofilament H, which are JNK substrates. Thus, in developing motor neurons, ATF2 may be involved in the regulation of JNK and p38 activation, potentially by the transcriptional upregulation of specific MAPK phosphatase genes, including Dusp1 (dual-specificity phosphatase 1).
Deletion of the DNA-binding domain of ATF7, in the presence of functional ATF2, has to date not exposed any discernible developmental phenotypes in mice [30] . However, ATF7 has an important role in the adult central nervous system, specifically in the regulation of gene expression in dorsal raphe nuclei of the brainstem in response to isolation stress [32] .
In contrast with the single deletions, the ATF2/ATF7 double deletion (Atf2 − / − ;Atf7 − / − ) results in severe hypoplasia in embryonic heart and liver, leading to lethality between embryonic day 11.5 and 12.5 [30] . This demonstrates that the two transcription factors share essential functions during embryonic development. Interestingly, the embryonic liver defect is very similar to, and occurs around the same time as, the one resulting from deletion of the JNK-activating kinase MKK4 (MAPK kinase 4) [33, 34] , but significantly before the liver defect observed in cJun-knockout embryos [35, 36] , suggesting that ATF2 and ATF7 are essential substrates for embryonic JNK signalling. ATF2/ATF7 mutant liver progenitor cells (hepatoblasts) undergo high rates of apoptosis in embryos as well as in culture. This high rate of apoptosis in cultured hepatoblasts can be rescued by the chemical inhibition of p38 activity, suggesting that the transcription factors may be involved in negative-feedback regulation of their upstream activating kinases. Double mutant livers express reduced levels of specific MAPK phosphatases, including Dusp1, Dusp8 and Dusp10, which are direct targets for ATF2/ATF7-mediated transcription. 
Attenuation in melanoma incidence
Relative increase in MITF expression [45] ATF2 in genetic models of cancer AP-1 and ATF transcription factors have been studied extensively for their potential involvement in tumour initiation and progression [37] . In a growing list of analyses, ATF2 has now also been identified in both tumour-promoting as well as tumour-suppressive roles (Table 1) . It is important to scrutinize the various model systems, especially in view of the complicating fact that ATF2 can be both a transcriptional regulator and dimerization partner of c-Jun. Thus, in some studies, deregulated ATF2 may not act in isolation, but rather may impinge on the composition and function of other AP-1 complexes in their regulation of oncogenic transformation.
Tumour-promoting roles of ATF2
In a study using mouse skin carcinoma cell lines, overexpression of a dominant-negative form of ATF2 was inhibitory for growth and transformation in culture, as well as in xenografts [38, 39] . At the molecular level, dominant-negative ATF2 led to reduced expression of c-Jun and ATF3, as well as cyclin D1 and cyclin A. However, phenotypes derived from the use of dominant-negative ATF2 may produce alterations in AP-1 dimer composition and consequently deficiencies in AP-1 (c-Jun)-mediated functions during transformation. The potential involvement of ATF2 in tumour-promoting activities has also been shown in melanoma. For example, HGF (hepatocyte growth factor) leads to activation of cyclin D1 expression and increased proliferation in melanoma cells, in a process that involves p38-and ATF2-dependent activities [40] .
ATF2 also provides resistance to UV-radiation-induced apoptosis in melanoma cells [41] . Furthermore, ATF2 is strongly associated with melanoma growth and metastasis [42, 43] . Expression of an N-terminal peptide of ATF2 reduced ATF2-dependent transcriptional activities, while increasing the activities of c-Jun. The change in the balance of ATF2/c-Jun transcriptional activities sensitized melanoma cells to apoptosis and inhibited their potential for growth and metastasis in graft models.
Further support for potential tumour-promoting activities by ATF2 was shown in a study on clinical samples of melanoma [44] . Here, a strong cytoplasmic ATF2 presence was associated with primary specimens in contrast with a strong nuclear ATF2 presence which was associated with metastasis. Thus ATF2 intracellular localization rather than expression may be a useful prognostic marker, with transcriptional inactive (cytoplasmic) ATF2 indicating better survival, in contrast with transcriptional active (nuclear) ATF2, indicating poor survival.
In a mouse model of melanoma, Shah et al. [45] introduced a conditional inactivation of ATF2 specifically in melanocytes [Atf2 f/f ;Tyr-Cre ER(T2) ] and induced melanoma development by crossing these mice to transgenic NRas Q64A ;INK4a − / − . As a result, mice expressing ATF2 transcriptionally deficient melanocytes developed significantly fewer melanomas compared with mice expressing wild-type ATF2. Expression analysis in melanocytes identified Mitf (microphthalmia transcription factor), a regulator of melanocyte biogenesis, as a gene that is normally down-regulated by ATF2-JunBdependent suppression of SOX10 transcription factor.
Tumour-suppressing roles of ATF2
In contrast with its role in promoting melanoma, an increasing number of genetic mouse models have identified roles for ATF2 in tumour suppression (Table 1) .
Atf2 heterozygote (Atf2 + / − ) mice had significantly increased rates of mammary tumour development [46] . In mammary tumours isolated from these mice, reduced expression of tumour-suppressor genes Gadd45a (growth arrest and DNA-damage-inducible 45α) and Maspin was observed. Gadd45α may induce apoptosis in response to hypoxia; Maspin, previously identified as a breast cancer tumour suppressor, has been shown to enhance cellular sensitivity to apoptotic stimuli. The link between ATF2 and Gadd45α and Maspin expression was strengthened further by the finding that, in samples of human breast cancer, ATF2 was found to be down-regulated compared with normal breast tissue and that weak ATF2 expression correlated with low levels of Maspin and Gadd45α.
Another study showed that, in a mouse model of chemically induced skin carcinogenesis {DMBA [7, 12-dimethylbenz [a] anthracene]/PMA} the specific inactivation of ATF2 in keratinocytes (Atf2 f/f ;K14-Cre) resulted in a significantly increased incidence of skin papillomas compared with wild-type [47] . ATF2-deficient keratinocytes, infected with oncogenic Ras (HRas V12 ) displayed an enhancement of the transformed phenotype, as shown by increased anchorage-independent growth in soft agar. HRas V12 -transformed ATF2-deficient keratinocytes exhibited a decreased expression of presenilin 1, which is required for proteolytic cleavage of the tumour suppressor Notch during the development of papillomas. Moreover, presenilin 1 can affect the phosphorylation and the stability of β-catenin 1. In ATF2-deficient papillomas, the reduced expression of presenilin 1 was correlated with the increased expression of β-catenin 1. Both up-regulation of β-catenin 1 and downregulation of Notch were implicated in the development of skin papillomas and in skin tumours [47, 48] .
ATF2 in human cancer
Mouse studies have, to date, provided significant insight into developmental and physiological functions of ATF2 and ATF7, and, in addition, suggested crucial roles for ATF2 in oncogenic transformation and tumorigenesis. However, critical questions remain with respect to their functions in human tumours ( Table 2) . As discussed above, analyses of tumour samples in breast cancer and melanoma suggest that ATF2 may exert tumour-suppressive functions and promoting functions respectively [44, 46] . Furthermore, enhanced presence of activated (Thr 71 phosphorylated) ATF2 was reported in common types of skin carcinoma, e.g. squamous cell carcinoma, Bowen's disease and basal cell carcinoma, suggesting an involvement of ATF2 in this type of tumour [49] . However, activation does not preclude a functional role for ATF2 in the development of this type of tumour, and further experimental testing will be required.
Interestingly, a recent global genomic analysis revealed a comprehensive array of gene mutations and determined core signalling pathways instrumental in pancreatic cancer development [50] . The study confirmed that mutations in Kras and associated genes are a prevailing feature of pancreatic tumours. In addition, in the tumour samples analysed, significant numbers of gene mutations have been identified in MAPK (JNK) components and also in ATF2. This may suggest that JNK signalling and/or ATF2 are instrumental in the progression of this cancer type, but this remains to be tested experimentally. ATF2 mutations have also been identified in mammary carcinomas (see Catalogue of Somatic Mutations in Cancer at http://www.sanger.ac.uk/genetics/CGP/cosmic/). It remains to be seen whether mutations identified in cancer cell lines have any significant effect on ATF2 function as well as on the tumour phenotype.
